Skip to content

Treatment of Post-dural Puncture Headache in Postpartum Patients: Sphenopalatine Ganglion Block to Epidural Blood Patch.

Treatment of Post-dural Puncture Headache in Postpartum Parturients: Comparing Sphenopalatine Ganglion Block to Epidural Blood Patch.

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02962427
Enrollment
4
Registered
2016-11-11
Start date
2016-11-30
Completion date
2018-12-31
Last updated
2020-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache

Brief summary

The purpose of this research study is to compare the effectiveness of a sphenopalatine ganglion block to an epidural blood patch for post-dural puncture headache relief in randomized postpartum parturients over a 48 hour period.

Detailed description

The purpose of this research study is to compare the effectiveness of a sphenopalatine ganglion block to an epidural blood patch for post-dural puncture headache relief in randomized postpartum parturients over a 48 hour period. A known dural puncture is defined as free flow of cerebral spinal fluid (CSF) during neuraxial placement. An unknown dural puncture is defined as neuraxial placement where free flow of CSF is not appreciated, however the patient is diagnosed with a post-dural puncture headache as defined by the International Classification of Headache Disorders.

Interventions

DRUGSphenopalatine ganglion Block

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18 years or age or greater 2. Postpartum obstetric parturient who was previously admitted to UCH. 3. Diagnosis of post-dural puncture headache based on the International Classification of Headache Disorders: 1. Dural puncture has been performed 2. Headache has developed within 5 days of the dural puncture 3. Not better accounted for by another ICHD-3 diagnosis. 4. Occurring immediately or within seconds of assuming an upright position and resolving quickly (within 1 minute) after lying horizontally.

Exclusion criteria

1. Refusal to participate in the study 2. Placement of an EBP within the past 5 days 3. Allergy and/or intolerance to any the study materials 4. Contraindications to an EBP 5. Plan for therapeutic anticoagulation post-partum

Design outcomes

Primary

MeasureTime frameDescription
Change in The Numerical Rating Scale Pain ScoreBaseline and 48 hoursThe Numerical Rating Scale (NRS) is commonly used to evaluate pain level in patients. It is presented as a numerical scale of 11 options, numbered 0-10, where the patient's pain intensity is represented by a number between the extremes of 0 = no pain at all to 10 = worst pain imaginable in numerical fashion. Its simplicity, reliability, and validity have made the NRS a useful tool for describing pain severity or intensity. The Investigators will consider a difference of 20% as a clinically significant change in pain score.

Countries

United States

Participant flow

Participants by arm

ArmCount
Sphenopalatine Ganglion Block
Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes. Sphenopalatine ganglion Block
3
Epidural Blood Patch
Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours. Epidural blood patch
1
Total4

Baseline characteristics

CharacteristicSphenopalatine Ganglion BlockEpidural Blood PatchTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
3 Participants1 Participants4 Participants
Age, Continuous29 Years
STANDARD_DEVIATION 4.36
30 Years
STANDARD_DEVIATION 0
29.25 Years
STANDARD_DEVIATION 3.59
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants0 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Region of Enrollment
United States
3 participants1 participants4 participants
Sex: Female, Male
Female
3 Participants1 Participants4 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 30 / 1
other
Total, other adverse events
0 / 30 / 1
serious
Total, serious adverse events
0 / 30 / 1

Outcome results

Primary

Change in The Numerical Rating Scale Pain Score

The Numerical Rating Scale (NRS) is commonly used to evaluate pain level in patients. It is presented as a numerical scale of 11 options, numbered 0-10, where the patient's pain intensity is represented by a number between the extremes of 0 = no pain at all to 10 = worst pain imaginable in numerical fashion. Its simplicity, reliability, and validity have made the NRS a useful tool for describing pain severity or intensity. The Investigators will consider a difference of 20% as a clinically significant change in pain score.

Time frame: Baseline and 48 hours

Population: Some subjects refused to give a 48 hour score.

ArmMeasureGroupValue (NUMBER)
Sphenopalatine Ganglion Block Baseline ScoreChange in The Numerical Rating Scale Pain ScoreSubject 0018 score on a scale
Sphenopalatine Ganglion Block Baseline ScoreChange in The Numerical Rating Scale Pain ScoreSubject 0034 score on a scale
Sphenopalatine Ganglion Block Baseline ScoreChange in The Numerical Rating Scale Pain ScoreSubject 00410 score on a scale
Sphenopalatine Ganglion Block 48 Hours ScoreChange in The Numerical Rating Scale Pain ScoreSubject 0010 score on a scale
Sphenopalatine Ganglion Block 48 Hours ScoreChange in The Numerical Rating Scale Pain ScoreSubject 0045 score on a scale
Epidural Blood Patch Baseline ScoreChange in The Numerical Rating Scale Pain ScoreSubject 0028 score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026